Detalhe da pesquisa
1.
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
Clin Lung Cancer
; 24(5): 474-482, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37076396
2.
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
JCO Precis Oncol
; 7: e2300191, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499192
3.
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Clin Lung Cancer
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195320
4.
The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.
Curr Opin Oncol
; 20(2): 155-61, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18300765
5.
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Lung Cancer
; 106: 1-7, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28285682
6.
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Clin Cancer Res
; 22(23): 5772-5782, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601595